McKesson is no longer asking investors to pay a wholesale multiple for a wholesale story. The first fiscal quarter shows specialty mix, practice-management scale, and a shrinking share count doing more work than the volume of boxes moving through the network. Revenue reached $105 billion. Adjusted earnings per share rose twenty percent. Management then lifted the full-year range only modestly, which reads as a decision to bank the beat rather than reset the long-run algorithm.
That gap between the print and the raise is the investment debate. GAAP diluted earnings were $5 versus $6 a year earlier. Redeemable minority interests in Medical-Surgical Solutions and Core Ventures marked higher, a non-cash charge that does not change the cash engine but does shrink the residual claim. Operating cash was negative in a seasonally weak quarter even as the company retired a large block of stock with an accelerated repurchase and new long-term debt. Specialty is earning. The capital structure is amplifying the per-share result.
Apollo closed a convertible preferred stake that values the medical-surgical unit at $13 billion. The planned Wellverse listing is the next portfolio test. Oncology and Multispecialty grew much faster than the core wholesale book, helped by Florida Cancer Specialists through Core Ventures and by PRISM Vision. Whether that mix keeps compounding after acquisition compares fade, or whether wholesale pricing and a softer med-surg print pull the multiple back toward Cardinal Health and Cencora, is the question the next several quarters resolve.